VBLT Overzicht aandelen
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Vascular Biogenics Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.16 |
| 52 Week Hoogtepunt | US$0.32 |
| 52 Week Laag | US$0.10 |
| Bèta | 0.71 |
| 11 maand verandering | -33.33% |
| 3 maanden verandering | -45.07% |
| 1 Jaar Verandering | 9.17% |
| 33 jaar verandering | -86.55% |
| 5 jaar verandering | -88.53% |
| Verandering sinds IPO | -97.33% |
Recent nieuws en updates
Recent updates
VBL Therapeutics receives non-compliance letter from Nasdaq
Sep 01VBL Therapeutics GAAP EPS of -$0.12
Aug 15VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals
Jul 19Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
May 18
Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump
Sep 03How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?
Mar 17How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?
Jan 28VBL Therapeutics expands the ovarian cancer trial in Europe
Dec 29Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?
Dec 24
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 19VBL Therapeutics EPS beats by $0.01, misses on revenue
Nov 16Rendement voor aandeelhouders
| VBLT | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -34.5% | -0.7% | -1.6% |
| 1Y | 9.2% | 19.8% | 30.8% |
Rendement versus industrie: VBLT exceeded the US Biotechs industry which returned -4.2% over the past year.
Rendement versus markt: VBLT underperformed the US Market which returned 14.1% over the past year.
Prijsvolatiliteit
| VBLT volatility | |
|---|---|
| VBLT Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: VBLT's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: VBLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Dror Harats | www.vblrx.com |
Vascular Biogenics Ltd. Samenvatting
| VBLT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$12.11m |
| Inkomsten(TTM) | -US$15.95m |
| Inkomsten(TTM) | US$481.00k |
25.2x
P/S-verhouding-0.8x
Koers/WinstverhoudingIs VBLT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| VBLT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$481.00k |
| Kosten van inkomsten | US$17.00k |
| Brutowinst | US$464.00k |
| Overige uitgaven | US$16.42m |
| Inkomsten | -US$15.95m |
Laatst gerapporteerde inkomsten
Jun 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.21 |
| Brutomarge | 96.47% |
| Nettowinstmarge | -3,317.05% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde VBLT op de lange termijn?
Bekijk historische prestaties en vergelijking